Skip to main content

Table 1 Patient characteristics

From: Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study

Characteristics Radiotherapy Chemoradiotherapyb Total
  (n = 10) % (n) (n = 5) % (n) (n = 15) % (n)
Age (years)
  Median (range) 62 (57–87) 53 (42–71) 61 (42–87)
Sex   
  Male 70 (7) 80 (4) 73 (11)
ECOG performance status
  1 0 20 (1) 1 (7)
  2 30 (3) 20 (1) 4 (26)
  3 70 (7) 60 (3) 10 (67)
Palliative prognostic index group [22]
  A 0 20 (1) 7 (1)
  B 70 (7) 20 (1) 53 (8)
  C 30 (3) 60 (3) 40 (6)
Histological type
  Well differentiated 10 (1) 20 (1) 13 (2)
  Moderately differentiated 50 (5) 20 (1) 40 (6)
  Poorly differentiated 40 (4) 60 (3) 47 (7)
Location
  Esophagogastric junction 20 (2) 40 (2) 27 (4)
  Gastric corpus 80 (8) 60 (3) 73 (11)
Metastatic sitea
  Lymph nodes 60 (6) 80 (4) 67 (10)
  Liver 60 (6) 60 (3) 60 (9)
  Peritoneum 30 (3) 60 (3) 40 (6)
Prior chemotherapeutic regimen
  0 10 (1) 0 7 (1)
  1 20 (2) 20 (1) 20 (3)
  2 10 (1) 20 (1) 13 (2)
  3 or more 60 (6) 60 (3) 60 (9)
Subsequent chemotherapyc
  Yes 20 (2) 60 (3) 33 (5)
Radiotherapy dose (Gy)
  30 80 (8) 80 (4) 80 (12)
  >30 10 (1) 20 (1) 13 (2)
  <30 10 (1) 0 7 (1)
Biologically effective dose (Gy10)
  Median (range) 39 (23.4–43.2) 39 (39–48) 39 (23–48)
  1. ECOG Eastern Cooperative Oncology Group
  2. aOverlapped data
  3. bPaclitaxel in 1; paclitaxel and trastuzumab in 1; methotrexate + 5-fluorouracil (5-FU) in 1; oxaliplatin + folinic acid + 5-FU in 1; low dose cisplatin + 5-FU in 1
  4. cPaclitaxel in 2; methotrexate + 5-FU in 1; docetaxel in 1; trastuzumab + lapatinib in 1